COMPARISON OF XANTHINE OXIDASE INHIBITORS IN GOUTY PATIENTS WITH HYPERURICEMIA

Objective: Febuxostat is more effective/superior to Allopurinol in reducing the serum uric acid (SUA) level in the treatment of hyperuricemic withgout.Methods: This randomized control study included 200 hyperuricemic patients with gout, at Multi-center study including Outdoor Departments ofMedicine from four different hospitals of Lahore, Pakistan. Patients age range 18-50 years diagnosis with hyperuricemia and gout, SUA >8 mg/dlwere included while severe renal impairment and alanine aminotransferase and aspartate aminotransferase patients were excluded from the study.Results: About 200 patients treated with hyperuricemic with gout were randomly divided into four groups (50%) patients were in each groupreceived different treatment. Out of 200 patients, 118 (59%) were male and 82 (41%) were female with mean age 42.37±9.47 years. Among theFebuxostat group, patients' success rate of lowering SUA level was found to be 32 (64%) as compared to Allopurinol 16 (32%). Drug compliance wassimilar among treatment groups, i.e. Allopurinol and Febuxostat while the trend toward drug compliance in Allopurinol + Vitamin C and Febuxostat +Vitamin C groups showed similar in number.Conclusion: Febuxostat is safe and effective to Allopurinol for the treatment of hyperuricemia with gout as the Febuxostat has a significant associationwith lowering SUA concentration <6 mg/dl. It is concluded that although Febuxostat is safe and effect alone in gouty patients, but it has somehow alittle effect with Vitamin C especially in patients who are feeble.Keywords: Febuxostat, Allopurinol, Serum uric acid.Â